Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Non-cash Items (2019 - 2026)

Kymera Therapeutics (KYMR) has disclosed Non-cash Items for 8 consecutive years, with $410.6 million as the latest value for Q1 2026.

  • For Q1 2026, Non-cash Items rose 367.12% year-over-year to $410.6 million; the TTM value through Mar 2026 reached $410.6 million, up 367.12%, while the annual FY2025 figure was $400.5 million, 309.86% up from the prior year.
  • Non-cash Items hit $410.6 million in Q1 2026 for Kymera Therapeutics, up from $400.5 million in the prior quarter.
  • Across five years, Non-cash Items topped out at $410.6 million in Q1 2026 and bottomed at $3.2 million in Q3 2022.
  • Average Non-cash Items over 5 years is $102.0 million, with a median of $75.2 million recorded in 2022.
  • Year-over-year, Non-cash Items soared 8374.47% in 2022 and then plummeted 97.18% in 2023.
  • Kymera Therapeutics' Non-cash Items stood at $55.9 million in 2022, then decreased by 11.28% to $49.6 million in 2023, then skyrocketed by 96.92% to $97.7 million in 2024, then soared by 309.86% to $400.5 million in 2025, then increased by 2.52% to $410.6 million in 2026.
  • According to Business Quant data, Non-cash Items over the past three periods came in at $410.6 million, $400.5 million, and $31.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.